Fu-Fang-Jin-Qian-Cao herbal granules protect against the calcium oxalate-induced renal EMT by inhibiting the TGF-β/smad pathway

References

• Chen H, Yang T, Wang MC, Chen DQ, Yang Y, Zhao YY. 2018. Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation. Phytomedicine. 42(15):207–218.
   PubMedGoogle Scholar
• Chen W, Liu WR, Hou JB, Ding JR, Peng ZJ, Gao SY, Dong X, Ma JH, Lin QS, Lu JR, et al. 2019. Metabolomic analysis reveals a protective effect of Fu-Fang-Jin-Qian-Chao herbal granules on oxalate-induced kidney injury. Biosci Rep. 39(2):1–15.
   Google Scholar
• Convento MB, Pessoa EA, Cruz E, da Glória MA, Schor N, Borges FT. 2017. Calcium oxalate crystals and oxalate induce an epithelial-to-mesenchymal transition in the proximal tubular epithelial cells: contribution to oxalate kidney injury. Sci Rep. 7:45740.
   PubMedGoogle Scholar
• Derynck R, Zhang YE. 2003. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 425(6958):577–584.
   PubMed Web of Science ®Google Scholar
• El-Zoghby ZM, Lieske JC, Foley RN, Bergstralh EJ, Li X, Melton LJ, Krambeck AE, Rule AD. 2012. Urolithiasis and the risk of ESRD. Clin J Am Soc Nephrol. 7(9):1409–1415.
   PubMed Web of Science ®Google Scholar
• Faust WC, Diaz M, Pohl HG. 2009. Incidence of post-pyelonephritic renal scarring: a meta-analysis of the dimercapto-succinic acid literature. J Urol. 181(1):290–298.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Moustakas A. 2012. Role of Smads in TGFβ signaling. Cell Tissue Res. 347(1):21–36.
   PubMed Web of Science ®Google Scholar
• Hou J, Chen W, Lu H, Zhao H, Gao S, Liu W, Dong X, Guo Z. 2018. Exploring the therapeutic mechanism of Desmodium styracifolium on oxalate crystal-induced kidney injuries using comprehensive approaches based on proteomics and network pharmacology. Front Pharmacol. 9:1–15.
   PubMed Web of Science ®Google Scholar
• Hu H, Chen W, Ding J, Jia M, Yin J, Guo Z. 2015. Fasudil prevents calcium oxalate crystal deposit and renal fibrogenesis in glyoxylate-induced nephrolithic mice. Exp Mol Pathol. 98(2):277–285.
   PubMed Web of Science ®Google Scholar
• Huang Y, Wen YM, Ma JH, Liu BM, Chen L. 2014. HPLC fingerprint of Pyrrosia calvata. Ching Med Plant. 5(2):46–50.
   PubMedGoogle Scholar
• Kho MC, Park JH, Han BH, Tan R, Yoon JJ, Kim HY, Ahn YM, Lee YJ, Kang DG, Lee HS. 2017. Plantago asiatica L. ameliorates puromycin aminonucleoside-induced nephrotic syndrome by suppressing inflammation and apoptosis. Nutrients. 9(4):386–313.
   PubMed Web of Science ®Google Scholar
• Kim TW, Kim YJ, Seo CS, Kim HT, Park SR, Lee MY, Jung JY. 2016. Elsholtzia ciliata (Thunb.) Hylander attenuates renal inflammation and interstitial fibrosis via regulation of TGF-ß and Smad3 expression on unilateral ureteral obstruction rat model. Phytomedicine. 23(4):331–339.
   PubMed Web of Science ®Google Scholar
• Kirkali Z, Rasooly R, Star RA, Rodgers GP. 2015. Urinary stone disease: progress, status, and needs. Urology. 86(4):651–653.
   PubMed Web of Science ®Google Scholar
• Liu Y. 2004. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 15(1):1–12.
   PubMed Web of Science ®Google Scholar
• Lovisa S, LeBleu VS, Tampe B, Sugimoto H, Vadnagara K, Carstens JL, Wu C-C, Hagos Y, Burckhardt BC, Pentcheva-Hoang T, et al. 2015. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 21(9):998–1009.
   PubMed Web of Science ®Google Scholar
• Lu Q, Ji XJ, Zhou YX, Yao XQ, Liu YQ, Zhang F, Yin XX. 2015. Quercetin inhibits the mTORC1/p70S6K signaling-mediated renal tubular epithelial-mesenchymal transition and renal fibrosis in diabetic nephropathy. Pharmacol Res. 99:237–247.
   PubMed Web of Science ®Google Scholar
• Meng LQ, Tang JW, Wang Y, Zhao JR, Shang MY, Zhang M, Liu SY, Qu L, Cai SQ, Li XM. 2011. Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy. Br J Pharmacol. 162(8):1805–1818.
   PubMed Web of Science ®Google Scholar
• Meng XM, Nikolic-Paterson DJ, Lan HY. 2016. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 12(6):325–338.
   PubMed Web of Science ®Google Scholar
• Meng XM, Ren GL, Gao L, Li HD, Wu WF, Li XF, Xu T, Wang XF, Ma TT, Li Z, et al. 2016. Anti-fibrotic effect of wogonin in renal tubular epithelial cells via Smad3-dependent mechanisms. Eur J Pharmacol. 789:134–143.
   PubMed Web of Science ®Google Scholar
• Meng XM, Tang PM, Li J, Lan HY. 2015. TGF-β/Smad signaling in renal fibrosis. Front Physiol. 6:82.
   PubMed Web of Science ®Google Scholar
• Mulay SR, Anders HJ. 2017. Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat Rev Nephrol. 13(4):226–240.
   PubMed Web of Science ®Google Scholar
• Okada A, Nomura S, Higashibata Y, Hirose M, Gao B, Yoshimura M, Itoh Y, Yasui T, Tozawa K, Kohri K. 2007. Successful formation of calcium oxalate crystal deposition in mouse kidney by intraabdominal glyoxylate injection. Urol Res. 35(2):89–99.
   PubMedGoogle Scholar
• Okada H, Ban S, Nagao S, Takahashi H, Suzuki H, Neilson EG. 2000. Progressive renal fibrosis in murine polycystic kidney disease: an immunohistochemical observation. Kidney Int. 58(2):587–597.
   PubMed Web of Science ®Google Scholar
• Pardede TR, Muchlisyam M. 2018. Analysis on calcium solubility in kidney stones (in vitro) and diuretic effect (in vivo) using corn silk (Zea mays L.) infuse. 2018. Asian J Pharm Clin Res. 11(13):80–83.
   Google Scholar
• Rodgers AL, Webber D, Ramsout R, Gohel MD. 2014. Herbal preparations affect the kinetic factors of calcium oxalate crystallization in synthetic urine: implications for kidney stone therapy. Urolithiasis. 42(3):221–225.
   PubMed Web of Science ®Google Scholar
• Romero V, Akpinar H, Assimos DG. 2010. Kidney stones: a global picture of prevalence, incidence, and associated risk factors. Rev Urol. 12(2–3):e86–e96.
   PubMedGoogle Scholar
• Shoag J, Halpern J, Goldfarb DS, Eisner BH. 2014. Risk of chronic and end stage kidney disease in patients with nephrolithiasis. J Urol. 192(5):1440–1445.
   PubMed Web of Science ®Google Scholar
• Taguchi K, Okada A, Kitamura H, Yasui T, Naiki T, Hamamoto S, Ando R, Mizuno K, Kawai N, Tozawa K, et al. 2014. Colony-stimulating factor-1 signaling suppresses renal crystal formation. J Am Soc Nephrol. 25(8):1680–1697.
   PubMed Web of Science ®Google Scholar
• Thakur R, Sharma A, Lingaraju MC, Begum J, Kumar D, Mathesh K, Kumar P, Singh TU, Kumar D. 2018. Ameliorative effect of ursolic acid on renal fibrosis in adenine-induced chronic kidney disease in rats. Biomed Pharmacother. 101:972–980.
   PubMed Web of Science ®Google Scholar
• Wang B, Liu D, Zhu QH, Li M, Chen H, Guo Y, Fan LP, Yue LS, Li LY, Zhao M. 2016. Rutin ameliorates kidney interstitial fibrosis in rats with obstructive nephropathy. Int Immunopharmacol. 35:77–84.
   PubMed Web of Science ®Google Scholar
• Wang XF, Zhang BH, Lu XQ, Wang RQ. 2019. Gastrin-releasing peptide receptor gene silencing inhibits the development of the epithelial-mesenchymal transition and formation of a calcium oxalate crystal in renal tubular epithelial cells in mice with kidney stones via the PI3K/Akt signaling pathway. J Cell Physiol. 234(2):1567–1577.
   PubMed Web of Science ®Google Scholar
• Wei X, Gao P, Pu Y, Li Q, Yang T, Zhang H, Xiong S, Cui Y, Li L, Ma X, et al. 2017. Activation of TRPV4 by dietary apigenin antagonizes renal fibrosis in deoxycorticosterone acetate (DOCA)-salt-induced hypertension. Clin Sci. 131(7):567–581.
   Web of Science ®Google Scholar
• Xiang S, Zhou J, Li J, Wang Q, Zhang Q, Zhao Z, Zhang L, Chen Z, Wang S. 2015. Antilithic effects of extracts from different polarity fractions of Desmodium styracifolium on experimentally induced urolithiasis in rats. Urolithiasis. 43(5):433–439.
   PubMed Web of Science ®Google Scholar
• Xu L, Adams-Huet B, Poindexter JR, Maalouf NM, Moe OW, Sakhaee K. 2017. Temporal changes in kidney stone composition and in risk factors predisposing to stone formation. J Urol. 197(6):1465–1471.
   PubMed Web of Science ®Google Scholar
• Yan Y, Feng Y, Li W, Che JP, Wang GC, Liu M, Zheng JH. 2014. Protective effects of quercetin and hyperoside on renal fibrosis in rats with unilateral ureteral obstruction. Exp Ther Med. 8(3):727–730.
   PubMed Web of Science ®Google Scholar
• Zeisberg M, Neilson EG. 2009. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest. 119(6):1429–1437.
   PubMed Web of Science ®Google Scholar
• Zeng G, Mai Z, Xia S, Wang Z, Zhang K, Wang L, Long Y, Ma J, Li Y, Wan SP, et al. 2017. Prevalence of kidney stones in China: an ultrasonography based cross-sectional study. BJU Int. 120(1):109–116.
   PubMed Web of Science ®Google Scholar
• Zhang C, Yuan J, Hu H, Chen W, Liu M, Zhang J, Sun S, Guo Z. 2017. Long non-coding RNA CHCHD4P4 promotes epithelial-mesenchymal transition and inhibits cell proliferation in calcium oxalate-induced kidney damage. Braz J Med Biol Res. 51(1):e6536.
   PubMed Web of Science ®Google Scholar
• Zhang CY, Zhu JY, Ye Y, Zhang M, Zhang LJ, Wang SJ, Song YN, Zhang H. 2017. Erhuang formula ameliorates renal damage in adenine-induced chronic renal failure rats via inhibiting inflammatory and fibrotic responses. Biomed Pharmacother. 95:520–528.
   PubMed Web of Science ®Google Scholar
• Zhou B, Mu J, Gong Y, Lu C, Zhao Y, He T, Qin Z. 2017. Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-β-mediated Nox4 expression. Redox Biol. 11:390–402.
   PubMed Web of Science ®Google Scholar
• Zhu X, Cheng YQ, Du L, Li Y, Zhang F, Guo H, Liu YW, Yin XX. 2015. Mangiferin attenuates renal fibrosis through down-regulation of osteopontin in diabetic rats. Phytother Res. 29(2):295–302.
   PubMed Web of Science ®Google Scholar